UroGen Pharma (URGN) Operating Margin (2017 - 2026)
UroGen Pharma's (URGN) quarterly Operating Margin came in at 39.76% in Q1 2026, up 14249.0% YoY from N/an in Q1 2025, and up 21.29% on a QoQ basis from 50.52% in Q4 2025.
Powered by 
Analysis
UroGen Pharma (URGN) Operating Margin (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 10 years of Operating Margin data on file, last reported at 39.76% in Q1 2026.
- Quarterly Operating Margin rose 14249.0% year-over-year to 39.76% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 77.02% (up 4049.0% YoY) and the FY2025 annual result came in at 113.73%, down 667.0% from the prior year.
- Operating Margin rose to 39.76% in Q1 2026, from 50.52% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 39.76% in Q1 2026 to a low of 182.26% in Q1 2025.
- A 5-year average of 106.34% and a median of 112.36% in 2022 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2022 — Operating Margin surged 18701 bps — and 2025, when it slumped 5290 bps.
- Tracing URGN's Operating Margin over 5 years: stood at 112.1% in 2022, then jumped by 45 bps to 62.09% in 2023, then plunged by 81 bps to 112.59% in 2024, then soared by 55 bps to 50.52% in 2025, then rose by 21 bps to 39.76% in 2026.
- The last three Operating Margin figures came in at 39.76% (Q1 2026), 50.52% (Q4 2025), and 99.65% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | UroGen Pharma | 2.23 Bn | 2.12 Bn | 65.88 Mn | 0.15% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.15% |
| Mar 31, 2026 | -39.76% |
| Dec 31, 2025 | -50.52% |
| Sep 30, 2025 | -99.65% |
| Jun 30, 2025 | -171.17% |
| Mar 31, 2025 | -182.26% |
| Dec 31, 2024 | -112.59% |
| Sep 30, 2024 | -69.61% |
| Jun 30, 2024 | -118.27% |
| Mar 31, 2024 | -137.05% |
| Dec 31, 2023 | -62.09% |
| Sep 30, 2023 | -64.74% |
| Jun 30, 2023 | -72.77% |
| Mar 31, 2023 | -128.23% |
| Dec 31, 2022 | -112.10% |
| Sep 30, 2022 | -112.36% |
| Jun 30, 2022 | -112.71% |
| Mar 31, 2022 | -161.88% |
| Dec 31, 2021 | -123.13% |
| Sep 30, 2021 | -206.50% |